Antimicrobial Photodynamic Therapy as a Potential Treatment Against COVID-19: A Case for Blue Light

2020 ◽  
Vol 38 (10) ◽  
pp. 577-578
Author(s):  
Chukuka S. Enwemeka ◽  
Terrance L. Baker ◽  
Jack V. Greiner ◽  
Violet V. Bumah ◽  
Daniela S. Masson-Meyers ◽  
...  
Author(s):  
Marcela Leticia Leal Gonçalves ◽  
Elaine Marcílio Santos ◽  
Ana Cláudia Muniz Renno ◽  
Anna Carolina Ratto Tempestini Horliana ◽  
Matheus de Almeida Cruz ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
pp. e15-e15
Author(s):  
Ardavan Etemadi ◽  
Mehdi Hamidain ◽  
Steven Parker ◽  
Nasim Chiniforush

Introduction: The aim of this article was to evaluate reports in the scientific literature that used antimicrobial photodynamic therapy (aPDT) with a blue light source and curcumin and riboflavin as photosensitizers in the management of periodontitis. Methods: The search was conducted in electronic databases, including PubMed, Web of Science, and Scopus, with the keywords "photodynamic therapy", "antimicrobial photodynamic therapy", "laser activated disinfection", "photoactivated disinfection", "light activated disinfection" "LED", "Periodontitis", "Curcumin", "Riboflavin", and "periodontitis" from 2012 to 2020. Results: After evaluating a total of 24 relevant articles, 13 articles were selected, full texts were read, and the data were extracted and placed in a table. Conclusion: Reviewing articles showed that curcumin as a photosensitizer activated by a blue wavelength is effective in the elimination of the various bacterial species involved in periodontal disease, and to the best of our knowledge, there is no study that has shown this substance does not reduce bacteria. According to the result of the articles, riboflavin as a photosensitizer activated by blue light can reduce bacteria that are involved in periodontitis, but other studies have reported that blue light alone can also reduce bacteria significantly. Therefore, more in-vitro and clinical trial studies are needed to give a more conclusive opinion on the effectiveness of riboflavin as a photosensitizer in the treatment of periodontitis.


2021 ◽  
Vol 122 ◽  
pp. 105024
Author(s):  
Marina Hirose ◽  
Yasuo Yoshida ◽  
Kouichiro Horii ◽  
Yoshiaki Hasegawa ◽  
Yasuyuki Shibuya

Author(s):  
Pier Poli ◽  
Francisley Avila Souza ◽  
Mattia Manfredini ◽  
Carlo Maiorana ◽  
Mario Beretta

Not required for Clinical case letters according to the authors' guidelines.


Antibiotics ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 869
Author(s):  
Beatriz Müller Nunes Souza ◽  
Juliana Guerra Pinto ◽  
André Henrique Correia Pereira ◽  
Alejandro Guillermo Miñán ◽  
Juliana Ferreira-Strixino

Staphylococccus aureus is a ubiquitous and opportunistic bacteria associated with high mortality rates. Antimicrobial photodynamic therapy (aPDT) is based on the application of a light source and a photosensitizer that can interact with molecular oxygen, forming Reactive Oxygen Species (ROS) that result in bacterial inactivation. This study aimed to analyze, in vitro, the action of aPDT with Photodithazine® (PDZ) in methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) strains. The strains were incubated with PDZ at 25, 50, 75, and 100 mg/L for 15 min and irradiated with fluences of 25, 50, and 100 J/cm2. The internalization of PDZ was evaluated by confocal microscopy, the bacterial growth by counting the number of colony-forming units, as well as the bacterial metabolic activity post-aPDT and the production of ROS. In both strains, the photosensitizer was internalized; the production of ROS increased when the aPDT was applied; there was a bacterial reduction compared to the control at all the evaluated fluences and concentrations; and, in most parameters, it was obtained complete inactivation with significant difference (p < 0.05). The implementation of aPDT with PDZ in clinical strains of S. aureus has resulted in its complete inactivation, including the MRSA strains.


Sign in / Sign up

Export Citation Format

Share Document